Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extens...
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
About this item
Full title
Author / Creator
Cohen, Jeffrey A , Khatri, Bhupendra , Barkhof, Frederik , Comi, Giancarlo , Hartung, Hans-Peter , Montalban, Xavier , Pelletier, Jean , Stites, Tracy , Ritter, Shannon , von Rosenstiel, Philipp , Tomic, Davorka , Kappos, Ludwig and TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group
Publisher
England: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
ObjectiveThe 12-month (M), phase 3, double-blind, randomised TRANSFORMS study demonstrated significant benefits of fingolimod 0.5 or 1.25 mg over interferon β-1a (IFNβ-1a) in patients with relapsing–remitting multiple sclerosis. We report the results of long-term (up to 4.5 years) extension of TRANSFORMS.MethodsPatients randomised to fingolimod (0....
Alternative Titles
Full title
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4853559
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4853559
Other Identifiers
ISSN
0022-3050
E-ISSN
1468-330X
DOI
10.1136/jnnp-2015-310597
